Immutep Ltd
IMMP2.860USD
-0.070-2.39%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
4.18BMarket Cap
LossP/E TTM
More Details of Immutep Ltd Company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Immutep Ltd Info
Ticker SymbolIMMP
Company nameImmutep Ltd
IPO dateJun 23, 1988
CEOVoigt (Marc)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJun 23
AddressLevel 32, Suite 32.07 Australia Square
CitySYDNEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2000
Phone61283157003
Websitehttps://www.immutep.com/
Ticker SymbolIMMP
IPO dateJun 23, 1988
CEOVoigt (Marc)
Company Executives of Immutep Ltd
Name
Name/Position
Position
Shareholding
Change
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Christian Mueller
Mr. Christian Mueller
Chief Development Officer
Chief Development Officer
--
--
Dr. Stephan Winckels
Dr. Stephan Winckels
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Eleanor Pearson
Ms. Eleanor Pearson
Investors Relation
Investors Relation
--
--
Name
Name/Position
Position
Shareholding
Change
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.39%
Meridian Wealth Management, LLC
0.29%
Sender Company & Partners, Inc
0.15%
Morgan Stanley & Co. LLC
0.11%
Other
98.41%
Shareholders
Shareholders
Proportion
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.39%
Meridian Wealth Management, LLC
0.29%
Sender Company & Partners, Inc
0.15%
Morgan Stanley & Co. LLC
0.11%
Other
98.41%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.98%
Investment Advisor
0.87%
Research Firm
0.19%
Hedge Fund
0.12%
Venture Capital
0.02%
Individual Investor
0.01%
Other
97.80%
Institutional Shareholding
Updated: 2 hours ago
Updated: 2 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
56
3.22M
2.19%
-430.02K
2025Q3
54
2.86M
1.94%
-666.36K
2025Q2
57
2.80M
1.91%
-1.07M
2025Q1
57
2.80M
1.92%
-1.15M
2024Q4
60
6.95M
4.78%
-4.23M
2024Q3
60
9.14M
6.30%
-2.51M
2024Q2
63
9.65M
6.65%
+2.67M
2024Q1
67
3.50M
2.94%
-1.44M
2023Q4
66
3.16M
2.65%
-1.77M
2023Q3
71
3.00M
2.53%
-4.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pengana Capital Group Limited
970.61K
0.66%
--
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
580.44K
0.39%
-19.49K
-3.25%
Sep 30, 2025
Meridian Wealth Management, LLC
420.90K
0.29%
+48.20K
+12.93%
Sep 30, 2025
Sender Company & Partners, Inc
215.86K
0.15%
+93.11K
+75.85%
Sep 30, 2025
Morgan Stanley & Co. LLC
160.47K
0.11%
+47.50K
+42.05%
Sep 30, 2025
AllianceBernstein L.P.
140.05K
0.1%
+60.49K
+76.04%
Jun 30, 2024
Susquehanna International Group, LLP
95.25K
0.06%
+36.94K
+63.36%
Sep 30, 2025
Verition Fund Management LLC
75.00K
0.05%
+31.00K
+70.45%
Sep 30, 2025
Jane Street Capital, L.L.C.
55.46K
0.04%
+55.46K
--
Sep 30, 2025
Steward Partners Investment Advisory, LLC
55.00K
0.04%
-6.00K
-9.84%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
DFA Dimensional International Small Cap ETF
0%
iShares Biotechnology ETF
Proportion0.02%
ActivePassive International Equity ETF
Proportion0%
DFA Dimensional International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immutep Ltd?
The top five shareholders of Immutep Ltd are:
Pengana Capital Group Limited holds 970.61K shares, accounting for 0.66% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 580.44K shares, accounting for 0.39% of the total shares.
Meridian Wealth Management, LLC holds 420.90K shares, accounting for 0.29% of the total shares.
Sender Company & Partners, Inc holds 215.86K shares, accounting for 0.15% of the total shares.
Morgan Stanley & Co. LLC holds 160.47K shares, accounting for 0.11% of the total shares.
Pengana Capital Group Limited holds 970.61K shares, accounting for 0.66% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 580.44K shares, accounting for 0.39% of the total shares.
Meridian Wealth Management, LLC holds 420.90K shares, accounting for 0.29% of the total shares.
Sender Company & Partners, Inc holds 215.86K shares, accounting for 0.15% of the total shares.
Morgan Stanley & Co. LLC holds 160.47K shares, accounting for 0.11% of the total shares.
What are the top three shareholder types of Immutep Ltd?
The top three shareholder types of Immutep Ltd are:
Pengana Capital Group Limited
BlackRock Institutional Trust Company, N.A.
Meridian Wealth Management, LLC
Pengana Capital Group Limited
BlackRock Institutional Trust Company, N.A.
Meridian Wealth Management, LLC
How many institutions hold shares of Immutep Ltd (IMMP)?
As of 2025Q4, 56 institutions hold shares of Immutep Ltd, with a combined market value of approximately 3.22M, accounting for 2.19% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.24%.
What is the biggest source of revenue for Immutep Ltd?
In --, the -- business generated the highest revenue for Immutep Ltd, amounting to -- and accounting for --% of total revenue.
